Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Deutsche Boerse AG
  5. Apontis Pharma AG
  6. News
  7. Summary
    APPH   DE000A3CMGM5

APONTIS PHARMA AG

(APPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

APONTIS PHARMA AG: Initial studies confirm that the share has a price potential of between 77% and 135%

06/18/2021 | 01:31am EDT

DGAP-News: APONTIS PHARMA AG / Key word(s): Research Update
APONTIS PHARMA AG: Initial studies confirm that the share has a price potential of between 77% and 135%

18.06.2021 / 07:30
The issuer is solely responsible for the content of this announcement.


APONTIS PHARMA AG: Initial studies confirm that the share has a price potential of between 77% and 135%

Monheim am Rhein, 18 June 2021.
The analysts at Hauck & Aufhäuser and Warburg Research have initiated coverage of the APONTIS PHARMA AG share (Ticker APPH / ISIN DE000A3CMGM5). In their initial study, the experts attest APONTIS an early-mover advantage in the market for Single Pills, which the company can convert into market share by accelerating the development of its broad product pipeline thanks to the fresh funds from the IPO, among other things.

Accordingly, Hauck & Aufhäuser analyst Aliaksandr Halitsa expects consolidated sales to grow by an average of 20% per year to EUR 96 million by the 2025 financial year, driven by market share gains and new products from the Single Pill pipeline. Due to the high scalability, the experts expect EBIT to increase to EUR 27 million in the same period, which corresponds to an EBIT margin of 28%.

Based on a DCF model, Hauck & Aufhäuser sees a price target of EUR 31.00. From the current price level of EUR 17.50, this corresponds to a price potential of 77%.

Warburg Research is even more confident in its initial assessment. The favorable global market trends such as the expanding Single Pill submarket, an aging society, the increasing relevance of combination therapies and stagnating R&D innovations in the industry provide APONTIS PHARMA with high growth potential, according to the experts.

The company currently has eight Single Pill products in its portfolio and has already achieved impressive growth rates of 250% to 800% with these products since market launch, according to Warburg analyst Dr. Christian Ehmann. Continuing on this path, APONTIS has four products in the short-term and 12 further projects for medium-term market entry in the pipeline, the expert added.

The Warburg analyst estimates sales of EUR 108.3 million by 2025 and considers an EBITDA of EUR 31.7 million to be achievable. Based on the current forecasts, Warburg Research derives a price target of EUR 41.00, which corresponds to a price potential of 135% based on the DCF model. The contact details of the analysts are available at the following link: https://ir.apontis-pharma.de/websites/apontispharma/English/2000/share-price.html

About APONTIS PHARMA:

APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three generic active ingredients in a single dosage form. APONTIS PHARMA develops, promotes and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe's leading pharmaceutical and chemical region. From here, the company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.

APONTIS PHARMA AG

Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein
Deutschland
apontis-pharma.de

APONTIS PHARMA Press-Contact

CROSS ALLIANCE
Sven Pauly
Sara Pinto
ir@apontis-pharma.de
T: +49 89 125 09 0330
www.crossalliance.de



18.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: APONTIS PHARMA AG
Alfred-Nobel-Str. 10
40789 Monheim
Germany
E-mail: info@apontis-pharma.de
Internet: https://apontis-pharma.de/
ISIN: DE000A3CMGM5
WKN: A3CMGM
Listed: Regulated Unofficial Market in Frankfurt (Scale)
EQS News ID: 1209368

 
End of News DGAP News Service

1209368  18.06.2021 

fncls.ssp?fn=show_t_gif&application_id=1209368&application_name=news&site_id=zonebourse_sftp

ę EQS 2021
All news about APONTIS PHARMA AG
07/28APONTIS PHARMA : reports accelerated growth in first half of 2021 - Single Pill ..
EQ
07/28PRESS RELEASE : APONTIS PHARMA reports accelerated growth in first half of 2021 ..
DJ
07/28Apontis Pharma AG Provides Earnings Guidance for the Financial Year 2021
CI
07/28Apontis Pharma AG Announces Unaudited Preliminary Earnings Results for the Fi..
CI
07/12PRESS RELEASE : APONTIS PHARMA marks further success in the roll-out of Single P..
DJ
07/12APONTIS PHARMA : marks further success in the roll-out of Single Pill therapy
EQ
06/18PRESS RELEASE : APONTIS PHARMA AG: Initial studies confirm that the share has a ..
DJ
06/18APONTIS PHARMA AG : Initial studies confirm that the share has a price potential..
EQ
06/10PRESS RELEASE : APONTIS PHARMA AG: Post-Stabilisation disclosure - Partial exerc..
DJ
06/10APONTIS PHARMA AG : Post-Stabilisation disclosure - Partial exercise of the Gree..
EQ
More news
Financials
Sales 2021 48,7 M 57,8 M 57,8 M
Net income 2021 2,90 M 3,44 M 3,44 M
Net cash 2021 28,8 M 34,1 M 34,1 M
P/E ratio 2021 60,9x
Yield 2021 -
Capitalization 179 M 212 M 212 M
EV / Sales 2021 3,08x
EV / Sales 2022 2,59x
Nbr of Employees 195
Free-Float -
Chart APONTIS PHARMA AG
Duration : Period :
Apontis Pharma AG Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 21,00 €
Average target price 36,00 €
Spread / Average Target 71,4%
EPS Revisions
Managers and Directors
Thomas Milz Chief Product Officer
Sector and Competitors
1st jan.Capi. (M$)
APONTIS PHARMA AG0.00%212
JOHNSON & JOHNSON9.42%453 313
ROCHE HOLDING AG13.38%337 105
PFIZER, INC.16.30%239 637
NOVARTIS AG0.28%225 343
ELI LILLY AND COMPANY44.22%221 348